Prednisolone is generally Not recommended for treating hepatic encephalopathy (HE) in cirrhosis. While some studies showed potential benefit in specific subsets of patients with HE, the evidence isn’t strong enough to support routine use. The risk of side effects, including hyperglycemia and increased risk of infections, often outweighs any potential benefits.
Instead of prednisolone, focus on managing the underlying cause of HE. This includes addressing precipitating factors such as gastrointestinal bleeding, infection, or electrolyte imbalances. Lactulose remains a cornerstone therapy for reducing ammonia levels. Dietary protein restriction might also be necessary in severe cases.
If HE is refractory to standard management, consider rifaximin, a non-absorbable antibiotic that targets gut bacteria and reduces ammonia production. Careful monitoring of liver function, mental status, and potential side effects is crucial throughout treatment.
Always consult with a hepatologist or gastroenterologist experienced in managing cirrhosis and HE. They can assess the individual patient’s needs and determine the most appropriate treatment strategy based on their specific condition and response to therapy. Clinical trials should be considered for patients who don’t respond to standard treatments.
